Therapeutic Targets Database



QSAR Model

| Target Name | CYP2A6 |
|------------------|-----------|
| Target TTD ID | TTDR01443 |

| Target Species | Human |
|-------------------|--|
| Chemical Type | Naphthalene and non-naphthalene derivatives |
| Mode of Action | Inhibitor |
| QSAR Model 1 | $pIC_{50(2A6)} = -0.234(\pm 1.666) - 3.380(\pm 0.847)FPSA_2 + 0.036(\pm 0.010)COSV + 0.082(\pm 0.041)Shadow_YZ$ $n_{\text{Training}} = 29, \text{ LOF} = 0.431, R^2 = 0.607, R_a^2 = 0.559,$ $F = 12.84(\text{df } 3, 25), Q^2 = 0.502, \text{ PRESS} = 9.950,$ $n_{\text{Test}} = 10, R_{\text{pred}}^2 = 0.667, r^2 = 0.785, r_0^2 = 0.648, r_m^2 = 0.494$ |
| QSAR Model 2 | $pIC_{50(2A6)} = 1.698 + 0.021COSV + 0.305A \log P - 0.004PPSA_2$ $n_{\text{Training}} = 29, \text{ LSE} = 0.282, R^2 = 0.561, R_a^2 = 0.508,$ $F = 34.39(\text{df } 1,27), Q^2 = 0.489, \text{ PRESS} = 10.196,$ $n_{\text{Test}} = 10, R_{\text{pred}}^2 = 0.714, r^2 = 0.778, r_0^2 = 0.721, r_m^2 = 0.592$ |
| QSAR Model 3 | $pIC_{50(2A6)} = -4.941(\pm 1.685) + 0.908(\pm 0.148)pIC_{50(2A5)} - 0.893(\pm 0.498)Density + 2.742(\pm 0.830)Fo + 0.500(\pm 0.167)Shadow_Ylength n_{Training} = 29, LOF = 0.320, R^2 = 0.757, R_a^2 = 0.687, F = 18.66(df 4, 24), Q^2 = 0.648, PRESS = 7.039, n_{Test} = 10, R_{pred}^2 = 0.869, r^2 = 0.842, r_0^2 = 0.842, r_m^2 = 0.842$ |

| QSAR Model 4 | $pIC_{50(2A6)}=0.052+0.536pIC_{50(2A5)}+0.328A\log P-0.011NCOSV$ |
|-----------------|--|
| | + 0.158Shadow_Ylength |
| | $n_{\text{Training}} = 29$, LSE = 0.192, $R^2 = 0.679$, $R_a^2 = 0.630$, |
| | $F = 57.07(df 1, 27), Q^2 = 0.610, PRESS = 7.796,$ |
| | $n_{\text{Test}} = 10, R_{\text{pred}}^2 = 0.867, r^2 = 0.883, r_0^2 = 0.866, r_m^2 = 0.768$ |
| Molecular | Access the following web-servers to compute molecular descriptors: MoDel and e-dragon |
| | Type of descriptor-Descriptor name: Definition |
| | Electronic-Apol: Sum of atomic polarizabilities; Dipole: Dipole moment; HOMO: Highest occupied |
| | molecular orbital energy; LUMO: Lowest unoccupied molecular orbital energy; Sr |
| | Superdelocalizability |
| | Shape-DIFFV: The difference between the volume of the individual molecule and the volume of the |
| | shape reference compound; COSV The common volume between each individual molecule and the |
| | molecule selected as the reference compound; Fo: The common overlap steric volume descriptor |
| | (COSV, see above) divided by the volume of the individual molecule; NCOSV: The difference |
| Descriptor | ShapeRMS: Root mean square (RMS) deviation between the individual molecule and the shape |
| | reference compound; SRVolume: The volume of the shape reference compound |
| | Spatial-RadOfGyration: ; Density: The ratio of molecular weight to molecular volume; PMI-mag: It |
| | calculates the principal moments of inertia about the principal axes of a molecule; Vm: Molecular |
| | volume inside the contact surface; Area: van der Waals area of a molecule; Jurs descriptors: These are |
| | calculated by mapping atomic partial charges on solvent-accessible surface areas of individual atoms; |
| | Shadow indices: This set of geometric descriptors helps to characterize the shape of the molecules |
| | Thermodynamic-AlogP: Log of the partition coefficient; Molref: Molar refractivity; AlogP98: Log |
| | of partition coefficient |
| Reference | Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA |
| | and G/PLS techniques. European Journal of Medicinal Chemistry 44 (2009) 1941-1951 |